CJC-1295 Pediatric Use Under Age 12: Off-Label Status, Safety Concerns, and What Clinicians Need to Know

What Is CJC-1295 and Why Does Its Mechanism Matter in Children?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of GRF 1-29 that incorporates a Drug Affinity Complex (DAC) technology. That DAC modification covalently binds the peptide to circulating albumin, extending its half-life from approximately 30 minutes (for native GHRH) to roughly 6 to 8 days. The result is sustained stimulation of pituitary somatotroph cells rather than the pulsatile GH release the body normally produces.

This distinction is not trivial in a child under 12. Pulsatile GH secretion is the physiological norm during childhood and is deeply integrated with skeletal growth, epiphyseal plate activity, and IGF-1 axis regulation. Replacing a pulsatile signal with a prolonged, supraphysiological one through a long-acting GHRH analog has never been rigorously studied in prepubescent children.

How CJC-1295 Differs From Native GHRH

Native GHRH has a plasma half-life of less than 5 minutes due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 resists this cleavage through an Ala2 substitution and the DAC modification. A 2006 phase I/II trial published in the Journal of Clinical Endocrinology and Metabolism (N=65 healthy adults) showed that a single 2 mg/kg intravenous dose of CJC-1295 produced mean 24-hour GH levels elevated for up to 6 days, with IGF-1 increases sustained for 9 to 11 days [1]. All subjects were adults aged 21 to 61. No pediatric cohort was included.

The Pulsatility Problem

Somatotropin secretion in children under 12 occurs in 6 to 12 discrete nocturnal pulses per day. Animal models show that continuous GHRH receptor stimulation can desensitize somatotrophs and paradoxically reduce GH output over time. A 1992 rodent study in the journal Endocrinology demonstrated that prolonged GHRH infusion suppressed subsequent pulsatile GH secretion by downregulating GHRH receptor expression [2]. Whether this receptor desensitization occurs in human prepubescent children exposed to long-acting GHRH analogs remains completely uncharacterized.

Regulatory Status: CJC-1295 Has No FDA Approval for Children or Adults

The FDA has not approved CJC-1295 for any indication in any age group. It is not listed in the FDA Orange Book as an approved drug product. It is not available through any FDA-cleared commercial pharmaceutical channel. Clinicians who prescribe it do so through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Compounding Pharmacy Considerations

Compounded CJC-1295 is prepared in 503A (patient-specific) or 503B (outsourcing facility) pharmacies. The FDA does not evaluate the safety, efficacy, or potency of compounded preparations before they reach patients. A 2023 FDA survey of compounded peptide products found potency variability ranging from 85% to 115% of labeled concentration across tested samples, with some preparations containing detectable impurities not present in research-grade material [3].

For an adult, that variability may have modest clinical consequences. For a 6- or 8-year-old child weighing 20 to 25 kg, a 15% potency overage in a weight-dosed peptide could meaningfully shift IGF-1 outside the age-adjusted normal range.

No Pediatric IND or NDA on Record

A search of ClinicalTrials.gov as of January 2025 returns zero registered trials of CJC-1295 in participants under 18. The FDA's drug database contains no investigational new drug (IND) applications for CJC-1295 in pediatric populations that have been made public. This is a complete absence of the data infrastructure that would ordinarily precede off-label use in a vulnerable population.

The Standard of Care for Pediatric Growth Hormone Deficiency

Children with confirmed growth hormone deficiency have well-characterized, FDA-approved treatment options. Understanding this standard of care is necessary context for evaluating any off-label alternative.

FDA-Approved Recombinant Human GH

Recombinant human growth hormone (rhGH, somatropin) has been FDA-approved for pediatric GHD since 1985. Multiple branded formulations are approved, including Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Lilly), Saizen (Merck Serono), and Omnitrope (Sandoz). Typical dosing for pediatric GHD ranges from 0.16 to 0.24 mg/kg/week administered via daily subcutaneous injection, per the 2016 Endocrine Society Clinical Practice Guideline on GHD [4].

That same guideline states: "We recommend treating children with GHD with GH at a dose that normalizes the height velocity and serum IGF-1 level." No mention of GHRH analogs, GHRH secretagogues, or CJC-1295 appears anywhere in the 2016 document.

Long-Term Safety Data for rhGH

The safety record for rhGH in children is extensive. The Pfizer International Growth Database (KIGS) collected data on more than 83,000 pediatric patients treated with somatropin across 27 years, making it one of the largest longitudinal pediatric endocrinology datasets in existence [5]. CJC-1295 has no comparable safety surveillance infrastructure for children of any age.

Newer Approved Options

Lonapegsomatropin (Skytrofa, Ascendis Pharma) was FDA-approved in August 2021 for pediatric GHD in children aged 1 year and older. It is a once-weekly prodrug formulation of somatropin. This approval was based on heiGHt trial data (N=161 prepubertal children) showing non-inferiority to daily somatropin on annualized height velocity at 52 weeks [6]. A once-weekly approved option exists. There is no rationale to substitute an unapproved, unstudied GHRH analog in a child who qualifies for lonapegsomatropin or daily somatropin.

Safety Concerns Specific to Children Under 12

Using any unapproved GH-axis-active compound in a child under 12 involves risks that cannot be fully characterized without controlled trial data. Several specific concerns apply to CJC-1295.

IGF-1 Dysregulation During Active Growth

IGF-1 is the primary effector of GH action on skeletal growth. In children under 12, serum IGF-1 values and IGF-binding protein-3 (IGFBP-3) are tightly age-referenced. Age- and sex-adjusted IGF-1 standard deviation scores (SDS) above +2 have been associated with increased colon polyp risk in adults and, in some cohort studies, with elevated cancer incidence. A 2022 meta-analysis in the Lancet Oncology (N=166,000 participants across 19 cohorts) found a hazard ratio of 1.09 per 1 SD increase in circulating IGF-1 for overall cancer incidence (95% CI 1.03 to 1.14, P<0.001) [7]. No pediatric-specific threshold for safe IGF-1 elevation from exogenous GHRH stimulation has been defined.

Epiphyseal Plate Sensitivity

The epiphyseal growth plates in children under 12 are highly responsive to GH and IGF-1. Disproportionate stimulation of the GH/IGF-1 axis during active skeletal growth could theoretically accelerate bone age advancement beyond chronological age, narrowing the window for linear height gain. This is a documented risk even with approved rhGH when doses exceed guideline ranges, and rhGH has decades of monitoring data to guide dose adjustments. CJC-1295 does not.

Hypothalamic-Pituitary Axis Immaturity

The hypothalamic-pituitary-somatotropic axis continues to mature through puberty. Introducing sustained exogenous GHRH receptor stimulation before this maturation is complete may alter the set points of endogenous GH pulsatility in ways that are not reversible. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that "perturbations of GHRH signaling during critical developmental windows may have lasting effects on somatotroph cell number and function," based on data from transgenic mouse models [8].

Absence of Pharmacokinetic Data in Children

No published pharmacokinetic or pharmacodynamic study of CJC-1295 has been conducted in humans under 18. The 2006 adult trial by Ionescu and Frohman is the primary human PK reference for CJC-1295 [1]. Pediatric pharmacokinetics differ from adult pharmacokinetics due to differences in body composition, albumin concentration, renal clearance rates, and volume of distribution. Applying adult dosing parameters to a prepubescent child is not pharmacologically justified.

Why Clinicians Are Seeing Interest in This Topic

Demand for GH-axis peptides has grown substantially in the direct-to-consumer telehealth market. A 2023 survey published in JAMA Internal Medicine found that approximately 4.2% of adults using telehealth platforms had been prescribed a compounded peptide therapy, most commonly for weight loss or body composition goals [9]. Parent-driven requests for pediatric access to these same compounds appear to follow this trend, though no formal survey data on pediatric peptide requests in telehealth have been published.

The commercial availability of CJC-1295 through wellness-oriented online pharmacies, and its marketing in fitness communities as a "growth hormone booster," has created a knowledge gap. Parents of short-statured children, or parents seeking to optimize growth in children who do not have diagnosed GHD, may encounter CJC-1295 as an apparent alternative to the diagnostic workup and specialist referral that GHD evaluation requires.

The Diagnostic Pathway That Comes First

A child under 12 presenting with short stature or growth deceleration requires a structured evaluation before any GH-axis intervention is considered. The Endocrine Society's 2016 guideline recommends the following sequence [4]:

• Measure height velocity over a minimum 6-month observation period
• Obtain bone age radiograph (left hand and wrist X-ray)
• Measure serum IGF-1 and IGFBP-3 (age- and sex-adjusted SDS)
• Conduct GH stimulation testing with at least two provocative agents if IGF-1 SDS is below minus 2
• Confirm pituitary anatomy with MRI if GH stimulation testing indicates deficiency

None of these steps involve CJC-1295. A child who completes this pathway and receives a confirmed GHD diagnosis has access to insured, FDA-approved, extensively monitored somatropin therapy. A child who does not complete this pathway and receives CJC-1295 instead has received an unapproved compound with no pediatric safety data and no regulatory oversight of their dosing.

What Providers Should Document If a Request Is Made

When a parent or caregiver requests CJC-1295 for a child under 12, the clinician's documentation should reflect a clear clinical rationale for declining the prescription. Several elements are worth including.

Informed Refusal Documentation

The prescribing clinician should document that the request was made, that the compound lacks FDA approval for pediatric use, that no controlled safety or efficacy data exist for children under 12, and that FDA-approved alternatives were discussed. This documentation protects both the patient and the provider.

Referral to Pediatric Endocrinology

Any child under 12 with a caregiver concerned about growth should be referred to a board-certified pediatric endocrinologist. The American Academy of Pediatrics and the Pediatric Endocrine Society both support specialist evaluation for children with height SDS below minus 2 or growth velocity below the 25th percentile for age [10]. A telehealth platform is not the appropriate setting for initiating GH-axis therapy in a prepubescent child regardless of which compound is under consideration.

No Compassionate Use Pathway Exists

Some off-label uses in children are supported by a compassionate use or expanded access framework when no approved option exists for the condition. That framework does not apply to CJC-1295 in GHD, because FDA-approved options do exist. It also does not apply to non-GHD indications (such as athletic performance or general wellness) because those are not recognized medical indications at any age.

Summary of Evidence Gaps

The table below summarizes what is known and what is absent in the CJC-1295 pediatric evidence base.

| Evidence Domain | Adults (18+) | Children Under 12 | |---|---|---| | Phase I/II human PK data | Available (2006, N=65) | None | | Randomized controlled efficacy trial | None (any indication) | None | | FDA-approved indication | None | None | | Long-term safety surveillance | None formal | None | | Guideline endorsement | None | None | | Compounding pharmacy availability | Yes (503A/503B) | Technically available; not clinically justified |

The absence of data in the pediatric column is not a reason to proceed with caution. It is a reason to decline the use of this compound in children under 12 entirely, and to redirect families toward the diagnostic and treatment pathways that have decades of safety data behind them.